Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Note 11 - Merger Agreement with Palvella Therapeutics, Inc. (Details Textual)

v3.24.4

Note 11 - Merger Agreement with Palvella Therapeutics, Inc. (Details Textual)	Jul. 23, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Jun. 30, 2016 $ / shares
Pieris Pharmaceutical Stockholders [Member] \| Pieris Pharmaceuticals, Inc. [Member]
Ownership Percentage		18.00%
Pieris Pharmaceuticals, Inc. [Member] \| Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	2,592,585
Class of Warrant or Right, Exercise Price, Subtracted Amount From Purchase Price, Per Share	$ 0.001
Class of Warrant or Right, Maximum Beneficial Percentage Ownership If Exercised	4.99%
Class of Warrant or Right, Maximum Percentage of Shares Outstanding if Exercised	9.99%
Class of Warrant or Right, Maximum Percentage Beneficial Ownership With Notice	19.99%
Pieris Pharmaceuticals, Inc. [Member] \| Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares	3,154,241
Shares Issued, Price Per Share (in dollars per share) \| $ / shares	$ 13.7299		$ 2.015
Shares Issued, Price Per Share, Multiplier	0.315478
Proceeds from Issuance or Sale of Equity	$ 78,900,000
Pieris Pharmaceuticals, Inc. [Member] \| Palvella [Member]
Contingency, Termination Fee Payable		$ 1,000,000
Contingency, Termination Fee, Receivable		$ 2,000,000
Pavella Stockholders [Member] \| Pieris Pharmaceuticals, Inc. [Member]
Ownership Percentage		82.00%
Palvella Merger [Member] \| Palvella [Member]
Company Valuation	95,000,000
Palvella Merger [Member] \| Pieris Pharmaceutical Stockholders [Member]
Company Valuation	21,000,000
Palvella Merger [Member] \| Pieris Pharmaceuticals, Inc. [Member]
Merger, Cash Threshold	$ 11,000,000

- Definition

Per share or per unit amount to be subtracted from purchase price to get exercise price of warrants.

+ References

No definition available.

+ Details

Name:	pvla_ClassOfWarrantOrRightExercisePriceSubtractedAmountFromPurchasePricePerShare
Namespace Prefix:	pvla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of maximum beneficial ownership if warrant exercised.

+ References

No definition available.

+ Details

Name:	pvla_ClassOfWarrantOrRightMaximumBeneficialPercentageOwnershipIfExercised
Namespace Prefix:	pvla_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of maximum beneficial ownership if warrant exercised if notice has been given.

+ References

No definition available.

+ Details

Name:	pvla_ClassOfWarrantOrRightMaximumPercentageBeneficialOwnershipWithNotice
Namespace Prefix:	pvla_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of maximum shares outstanding if warrant exercised.

+ References

No definition available.

+ Details

Name:	pvla_ClassOfWarrantOrRightMaximumPercentageOfSharesOutstandingIfExercised
Namespace Prefix:	pvla_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the valuation of a company.

+ References

No definition available.

+ Details

Name:	pvla_CompanyValuation
Namespace Prefix:	pvla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the termination fee payable if the company terminates an agreement.

+ References

No definition available.

+ Details

Name:	pvla_ContingencyTerminationFeePayable
Namespace Prefix:	pvla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the termination fee receivable from the termination of an agreement.

+ References

No definition available.

+ Details

Name:	pvla_ContingencyTerminationFeeReceivable
Namespace Prefix:	pvla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the threshold amount of cash in a merger.

+ References

No definition available.

+ Details

Name:	pvla_MergerCashThreshold
Namespace Prefix:	pvla_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Ownership percentage

+ References

No definition available.

+ Details

Name:	pvla_OwnershipPercentage
Namespace Prefix:	pvla_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The multiplier for price per share of shares issued.

+ References

No definition available.

+ Details

Name:	pvla_SharesIssuedPricePerShareMultiplier
Namespace Prefix:	pvla_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Name:	us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=pvla_PierisPharmaceuticalStockholdersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=pvla_PierisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=pvla_PierisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=pvla_PrefundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=pvla_SecuritiesPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pvla_PalvellaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=pvla_PavellaStockholdersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=pvla_PalvellaMergerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=pvla_PalvellaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: